Adaptive Biotechnologies Corp (NAS:ADPT)
$ 3.31 -0.14 (-4.06%) Market Cap: 487.79 Mil Enterprise Value: 296.04 Mil PE Ratio: 0 PB Ratio: 1.77 GF Score: 72/100

Adaptive Biotechnologies Corp at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 08:40PM GMT
Release Date Price: $41.9 (-4.18%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon, everyone, and thanks for joining us for the last session of our health care conference. We're pleased to have Adaptive Biotechnologies with us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, by the way. And with us from Adaptive, we have Chad Robins, CEO of the company.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

And with that, Chad, maybe as we start here. Adaptive has 2 commercial products, immunoSEQ and clonoSEQ. Can you briefly remind us of the settings in which they're used and the growth levers for both of these on the [ford]?

Chad M. Robins
Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman

Sure. Happy to. First, Salveen, thank you for having me. And hopefully, I can do you justice by batting cleanup in the last spot here. In terms of the 2 commercial products, so immunoSEQ is our research product offering that leverages the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot